nafamostat has been researched along with Flushing in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Flushing: A transient reddening of the face that may be due to fever, certain drugs, exertion, or stress.
Excerpt | Relevance | Reference |
---|---|---|
"For each of 10 patients with ulcerative colitis, we used four types of anticoagulants sequentially [NM (30-50 mg), heparin, low-molecular-weight heparin (LMWH) and NM (1 mg), and LMWH] for LCAP." | 2.73 | Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis. ( Hiraishi, H; Hoshino, M; Kanke, K; Nakano, M; Terano, A; Tominaga, K, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kanke, K | 1 |
Hoshino, M | 1 |
Tominaga, K | 1 |
Nakano, M | 1 |
Terano, A | 1 |
Hiraishi, H | 1 |
1 trial available for nafamostat and Flushing
Article | Year |
---|---|
Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis.
Topics: Anticoagulants; Benzamidines; Biocompatible Materials; Biomarkers; Bradykinin; Colitis, Ulcerative; | 2007 |